🇺🇸 FDA
Patent

US 11407789

Cell-penetrating compstatin analogs and uses thereof

granted A61KA61K38/00A61K47/645

Quick answer

US patent 11407789 (Cell-penetrating compstatin analogs and uses thereof) held by Apellis Pharmaceuticals, Inc. expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Apellis Pharmaceuticals, Inc.
Grant date
Tue Aug 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K38/00, A61K47/645